Statistical Center for HIV/AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Lancet. 2010 Jun 12;375(9731):2092-8. doi: 10.1016/S0140-6736(10)60705-2. Epub 2010 May 26.
High plasma HIV-1 RNA concentrations are associated with increased risk of HIV-1 transmission. Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners.
Participants in our prospective cohort analysis were from a randomised placebo-controlled trial that enrolled heterosexual African adults who were seropositive for both HIV-1 and herpes simplex virus type 2, and their HIV-1 seronegative partners. At enrolment, HIV-1 infected participants had CD4 counts of 250 cells per microL or greater and did not meet national guidelines for ART initiation; during 24 months of follow-up, CD4 counts were measured every 6 months and ART was initiated in accordance with national guidelines. Uninfected partners were tested for HIV-1 every 3 months. The primary outcome was genetically-linked HIV-1 transmission within the study partnership. We assessed rates of HIV-1 transmission by ART status of infected participants.
3381 couples were eligible for analysis. 349 (10%) participants with HIV-1 initiated ART during the study, at a median CD4 cell count of 198 (IQR 161-265) cells per microL. Only one of 103 genetically-linked HIV-1 transmissions was from an infected participant who had started ART, corresponding to transmission rates of 0.37 (95% CI 0.09-2.04) per 100 person-years in those who had initiated treatment and 2.24 (1.84-2.72) per 100 person-years in those who had not-a 92% reduction (adjusted incidence rate ratio 0.08, 95% CI 0.00-0.57, p=0.004). In participants not on ART, the highest HIV-1 transmission rate (8.79 per 100 person-years) was from those with CD4 cell counts lower than 200 cells per microL. In couples in whom the untreated HIV-1 infected partner had a CD4 cell count greater than 200 cells per microL, 66 (70%) of 94 transmissions occurred when plasma HIV-1 concentrations exceeded 50 000 copies per mL.
Low CD4 cell counts and high plasma HIV-1 concentrations might guide use of ART to achieve an HIV-1 prevention benefit. Provision of ART to HIV-1 infected patients could be an effective strategy to achieve population-level reductions in HIV-1 transmission.
Bill & Melinda Gates Foundation; US National Institutes of Health.
高血浆 HIV-1 RNA 浓度与 HIV-1 传播风险增加相关。抗逆转录病毒治疗(ART)的启动降低了血浆 HIV-1 浓度。我们旨在评估感染 HIV-1 的患者使用 ART 对其未感染伴侣传播风险的影响。
我们前瞻性队列分析的参与者来自一项随机安慰剂对照试验,该试验招募了同时感染 HIV-1 和单纯疱疹病毒 2 型的非洲异性恋成年人,以及他们 HIV-1 阴性的伴侣。在入组时,HIV-1 感染参与者的 CD4 计数为每微升 250 个细胞或更高,且不符合国家 ART 启动指南;在 24 个月的随访期间,每 6 个月测量一次 CD4 计数,并根据国家指南启动 ART。未感染的伴侣每 3 个月接受一次 HIV-1 检测。主要结局是研究伴侣关系中遗传相关的 HIV-1 传播。我们根据感染参与者的 ART 状况评估了 HIV-1 传播率。
3381 对夫妇符合分析条件。349 名(10%)HIV-1 感染者在研究期间开始接受 ART,中位 CD4 细胞计数为 198(IQR 161-265)个细胞/微升。仅在 103 例遗传相关 HIV-1 传播中有 1 例来自已开始 ART 的感染参与者,这对应于已开始治疗者每 100 人年 0.37(95%CI 0.09-2.04)和未开始治疗者每 100 人年 2.24(1.84-2.72)的传播率-92%减少(调整发病率比 0.08,95%CI 0.00-0.57,p=0.004)。在未接受 ART 的参与者中,HIV-1 传播率最高(8.79 人年/100 人)来自 CD4 细胞计数低于每微升 200 个细胞的参与者。在未接受治疗的 HIV-1 感染伴侣的 CD4 细胞计数大于每微升 200 个细胞的夫妇中,当血浆 HIV-1 浓度超过每毫升 50000 拷贝时,66(70%)例传播发生。
低 CD4 细胞计数和高血浆 HIV-1 浓度可能指导 ART 的使用以实现 HIV-1 预防效益。为 HIV-1 感染者提供 ART 可能是实现人群中 HIV-1 传播减少的有效策略。
比尔及梅琳达·盖茨基金会;美国国立卫生研究院。